Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 4630

Sort by

Sort Order Select

Journal Articles

Prognostic factors for CNS control in children with acute lymphoblastic leukemia treated without cranial irradiation

Blood (2021) 138 (4): 331–343.

https://doi.org/10.1182/blood.2020010438

Published: 2021

Includes: Supplemental data

Journal Articles

Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project

Ranjana H. Advani, Tetiana Skrypets, Monica Civallero, Michael A. Spinner, Martina Manni, Won Seog Kim, Andrei R. Shustov, Steven M. Horwitz, Felicitas Hitz, Maria Elena Cabrera, Ivan Dlouhy, José Vassallo, Stefano A. Pileri, Giorgio Inghirami, Silvia Montoto, Umberto Vitolo, John Radford, Julie M. Vose, Massimo Federico

Blood (2021) 138 (3): 213–220.

https://doi.org/10.1182/blood.2020010387

Published: 2021

Includes: Supplemental data

Journal Articles

What can Heraclitus tell us about AML?

Arnold Ganser

Blood (2021) 137 (20): 2719–2720.

https://doi.org/10.1182/blood.2021011264

Published: 2021

Journal Articles

Prognostic significance of concurrent gene mutations in intensively treated patients with IDH -mutated AML: an ALFA study

Blood (2021) 137 (20): 2827–2837.

https://doi.org/10.1182/blood.2020010165

Published: 2021

Includes: Supplemental data

Journal Articles

Syndecan-1 and stromal heparan sulfate proteoglycans: key moderators of plasma cell biology and myeloma pathogenesis

Zemin Ren, Marcel Spaargaren, Steven T. Pals

Blood (2021) 137 (13): 1713–1718.

https://doi.org/10.1182/blood.2020008188

Published: 2021

Journal Articles

del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma

Blood (2021) 137 (9): 1192–1195.

https://doi.org/10.1182/blood.2020008346

Published: 2021

Includes: Supplemental data

Journal Articles

Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax

Blood (2020) 135 (26): 2402–2412.

https://doi.org/10.1182/blood.2019004492

Published: 2020

Includes: Supplemental data

Journal Articles

Prognostic factors for VTE and bleeding in hospitalized medical patients: a systematic review and meta-analysis

Andrea J. Darzi, Samer G. Karam, Rana Charide, Itziar Etxeandia-Ikobaltzeta, Mary Cushman, Michael K. Gould, Lawrence Mbuagbaw, Frederick A. Spencer, Alex C. Spyropoulos, Michael B. Streiff, Scott Woller, Neil A. Zakai, Federico Germini, Marta Rigoni, Arnav Agarwal, Rami Z. Morsi, Alfonso Iorio, Elie A. Akl, Holger J. Schünemann

Blood (2020) 135 (20): 1788–1810.

https://doi.org/10.1182/blood.2019003603

Published: 2020

Includes: Supplemental data

Journal Articles

Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuria

Christoph R. Kimmich, Tobias Terzer, Axel Benner, Tobias Dittrich, Kaya Veelken, Alexander Carpinteiro, Timon Hansen, Hartmut Goldschmidt, Anja Seckinger, Dirk Hose, Anna Jauch, Stefan Wörner, Jörg Beimler, Carsten Müller-Tidow, Ute Hegenbart, Stefan O. Schönland

Blood (2020) 135 (18): 1517–1530.

https://doi.org/10.1182/blood.2019003633

Published: 2020

Includes: Supplemental data

Journal Articles

Erdheim-Chester disease

Julien Haroche, Fleur Cohen-Aubart, Zahir Amoura

Blood (2020) 135 (16): 1311–1318.

https://doi.org/10.1182/blood.2019002766

Published: 2020

Journal Articles

IKZF1 deletions in pediatric acute lymphoblastic leukemia: still a poor prognostic marker?

Martin Stanulla, Hélène Cavé, Anthony V. Moorman

Blood (2020) 135 (4): 252–260.

https://doi.org/10.1182/blood.2019000813

Published: 2020

Journal Articles

Treatment-naive CLL: lessons from phase 2 and phase 3 clinical trials

Jennifer A. Woyach

Blood (2019) 134 (21): 1796–1801.

https://doi.org/10.1182/blood.2019001321

Published: 2019

Journal Articles

Serum Albumin Level, but Not Nutritional Risk Index Predicts Outcomes in Acute Leukemia Patients after Allo-HSCT

Mikhail Yu. Drokov, MD PhD, Natalia N. Popova, MD, Vera A. Vasilyeva, MD PhD, Ekaterina D. Mikhaltsova, MD PhD, Olga M. Koroleva, MD, Zoya V. Konova, Anna A. Dmitrova, MD, Olga S. Starikova, MD, Ulyana V. Maslikova, MD, Maria V. Dovydenko, MD PhD, Ekterina Usikova, Larisa A. Kuzmina, MD PhD, Elena N. Parovichnikova, MD PhD, Valery G. Savchenko, MD PhD academician

Blood (2019) 134 (Supplement_1): 1987.

https://doi.org/10.1182/blood-2019-126822

Published: 2019

Journal Articles

Alternative Donor and Disease-Specific Conditioning Regimen Hematopoietic Stem Cell Transplantation for Inherited Bone Marrow Failure Syndromes

Fang Xu, Min Xiong, Ruijuan Sun, Yanli Zhao, Jianping Zhang, Xingyu Cao, Deyan Liu, Zhijie Wei, Jiarui Zhou, Yue Lu, Peihua Lu, Daopei Lu

Blood (2019) 134 (Supplement_1): 2047.

https://doi.org/10.1182/blood-2019-125695

Published: 2019

Journal Articles

A Rise in Plasma Coagulability during the First 3 Months Following Provoked Venous Thromboembolism Is Associated with the Development of Post-Thrombotic Syndrome in Children and Young Adults: Analysis of the Kids-DOTT Multicenter Trial-Derived Biobank

Marisol Betensky, MDMPH, Ernest Amankwah, PhD, Stephanie Brandal, Allen Everett, MD, Neil A Goldenberg, MD PhD

Blood (2019) 134 (Supplement_1): 2424.

https://doi.org/10.1182/blood-2019-131821

Published: 2019

Journal Articles

Lymphoma-Specific Venous Thromboembolism Score (LyV-Score): Use of Lymphoma Subtype to Refine Risk Prediction

Shufen Cao, Gouri Dharmavaram, Kirsten M Boughan, DO, Brenda Cooper, MD, Molly M Gallogly, MD PhD, Ehsan Malek, MD, Leland Metheny, III, MD, Folashade Otegbeye, MBBChir,MPH, Benjamin K. Tomlinson, MD, Marcos de Lima, MD, Pingfu Fu, Paolo F Caimi, MD

Blood (2019) 134 (Supplement_1): 4770.

https://doi.org/10.1182/blood-2019-131527

Published: 2019

Journal Articles

Flowsom: An R-Based Evaluation Strategy for Flow Cytometry-Based Measurable Residual Disease (MRD) Diagnostics in Acute Myeloid Leukemia (AML)

Veit Bücklein, MD, Alexandra Stein, Benjamin Tast, PhD, Thomas Koehnke, MD, Karsten Spiekermann, MD, Francis Lacombe, MD PhD, Marion Subklewe, MD

Blood (2019) 134 (Supplement_1): 4656.

https://doi.org/10.1182/blood-2019-129866

Published: 2019

Journal Articles

First Analysis of the UKALL14 Phase 3 Randomised Trial to Determine If the Addition of Rituximab to Standard Induction Chemotherapy Improves EFS in Adults with Precursor B-ALL (CRUK/09/006)

David I Marks, MBBS, PhD FRCPath, Amy A. Kirkwood, MSc, Clare J Rowntree, MBBS, PhD FRCP, FRCPath, Melanie Aguiar, BSc, Katharine E Bailey, MBBS, FRCPath, MA, MRCP, Brendan Beaton, MD, Laura Clifton-Hadley, PhDBSc, Emma Lawrie, BSc, SooWah Lee, MSc, Andrew K McMillan, FRCP, Anthony V. Moorman, PhD, Rachel J. Mitchell, MSc, Pip Patrick, PhDMSc,MA, Tobias F Menne, MD PhD FRCPath, Paul Smith, Bela Wrench, MBBS, MD MRCP, FRCPath, Krisztina Zuborne Alapi, MSc, Adele K. Fielding, MBBS,PhDFRCP,FRCPath

Blood (2019) 134 (Supplement_1): 739.

https://doi.org/10.1182/blood-2019-123374

Published: 2019

Journal Articles

Achievement of Complete Remission (CR) with Measurable Residual Disease (MRD) Negativity Is Highly Prognostic in Patients (pts) with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) Receiving First Salvage Chemotherapy

Blood (2019) 134 (Supplement_1): 735.

https://doi.org/10.1182/blood-2019-122779

Published: 2019

Journal Articles

Retrospective and Prospective Study of Childhood Autoimmune Hemolytic Anemia. a Preliminary Report from the Red Cell Working Group of the Paediatric Hemato-Oncology Italian Associations (AIEOP)

Blood (2019) 134 (Supplement_1): 947.

https://doi.org/10.1182/blood-2019-124735

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Prognostic factors for CNS control in children with acute lymphoblastic leukemia treated without cranial irradiation

Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project

What can Heraclitus tell us about AML?

Prognostic significance of concurrent gene mutations in intensively treated patients with IDH -mutated AML: an ALFA study

Syndecan-1 and stromal heparan sulfate proteoglycans: key moderators of plasma cell biology and myeloma pathogenesis

del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma

Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax

Prognostic factors for VTE and bleeding in hospitalized medical patients: a systematic review and meta-analysis

Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuria

Erdheim-Chester disease

IKZF1 deletions in pediatric acute lymphoblastic leukemia: still a poor prognostic marker?

Treatment-naive CLL: lessons from phase 2 and phase 3 clinical trials

Serum Albumin Level, but Not Nutritional Risk Index Predicts Outcomes in Acute Leukemia Patients after Allo-HSCT

Alternative Donor and Disease-Specific Conditioning Regimen Hematopoietic Stem Cell Transplantation for Inherited Bone Marrow Failure Syndromes

A Rise in Plasma Coagulability during the First 3 Months Following Provoked Venous Thromboembolism Is Associated with the Development of Post-Thrombotic Syndrome in Children and Young Adults: Analysis of the Kids-DOTT Multicenter Trial-Derived Biobank

Lymphoma-Specific Venous Thromboembolism Score (LyV-Score): Use of Lymphoma Subtype to Refine Risk Prediction

Flowsom: An R-Based Evaluation Strategy for Flow Cytometry-Based Measurable Residual Disease (MRD) Diagnostics in Acute Myeloid Leukemia (AML)

First Analysis of the UKALL14 Phase 3 Randomised Trial to Determine If the Addition of Rituximab to Standard Induction Chemotherapy Improves EFS in Adults with Precursor B-ALL (CRUK/09/006)

Achievement of Complete Remission (CR) with Measurable Residual Disease (MRD) Negativity Is Highly Prognostic in Patients (pts) with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) Receiving First Salvage Chemotherapy

Retrospective and Prospective Study of Childhood Autoimmune Hemolytic Anemia. a Preliminary Report from the Red Cell Working Group of the Paediatric Hemato-Oncology Italian Associations (AIEOP)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only